Skip to main content

Table 8 Biodex data (except for walking speed, higher scores indicate less impairment).

From: S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]

   Baseline SAMe Celecoxib  
Variable N+ Mean (SD) Mean (SD) Mean (SD) Stdif.
Isometric 60 degrees
Peak flexion 45 66.7 (30.6) 80.2* (30.0) 77.5* (29.2) 0.21
Peak extension 45 92.4 (40.8) 116.6* (52.0) 112.5* (50.3) 0.19
Isokinetic 60 degrees
Peak flexion 45 40.5 (21.2) 54.8* (26.5) 52.3* (20.9) 0.16
Peak extension 45 84.2 (43.5) 107.1* (43.0) 102.4* (39.0) 0.24
Average flexion 45 22.2 (16.8) 32.1* (18.4) 29.9* (15.2) 0.19
Average extension 45 48.0 (27.5) 64.3* (28.3) 62.3* (26.4) 0.14
Isokinetic 180 degrees
Peak flexion 45 30.7 (15.7) 39.0* (16.3) 37.9* (15.1) 0.13
Peak extension 45 57.0 (29.5) 72.3* (31.0) 69.3* (28.0) 0.19
Average flexion 45 25.3 (27.8) 42.7* (32.4) 39.3* (29.3) 0.18
Average extension 45 76.5 (53.0) 109.6* (56.4) 105.6* (50.9) 0.14
Walking Speed 42 3.12 (1.52) 2.63* (0.91) 2.56* (0.69) -0.14
  1. Stdif: Standardized difference scores – positive numbers indicate a better response with SAMe. +Sample sizes are less than 57 due to missing data in either Phase 1 or Phase 2. *Difference between baseline and treatment is statistically significant (p < 0.05). No statistically significant differences were observed between SAMe and Celecoxib.